| 前收盘价格 | 39.48 |
| 收盘价格 | 40.63 |
| 成交量 | 576,691 |
| 平均成交量 (3个月) | 636,593 |
| 市值 | 2,194,182,144 |
| 市盈率 (P/E TTM) | 34.80 |
| 预期市盈率 (P/E Forward) | 20.33 |
| 价格/销量 (P/S) | 1.76 |
| 股市价格/股市净资产 (P/B) | 1.66 |
| 52周波幅 | |
| 利润日期 | 29 Apr 2025 - 5 May 2025 |
| 营业毛利率 | 5.05% |
| 营业利益率 (TTM) | 11.05% |
| 稀释每股收益 (EPS TTM) | 1.16 |
| 季度收入增长率 (YOY) | 3.80% |
| 季度盈利增长率 (YOY) | 242.10% |
| 总债务/股东权益 (D/E MRQ) | 51.26% |
| 流动比率 (MRQ) | 2.88 |
| 营业现金流 (OCF TTM) | 183.04 M |
| 杠杆自由现金流 (LFCF TTM) | 143.42 M |
| 资产报酬率 (ROA TTM) | 4.19% |
| 股东权益报酬率 (ROE TTM) | 4.87% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Devices (US) | 混合的 | 混合的 |
| Medical Devices (全球的) | 混合的 | 混合的 | |
| 股票 | LivaNova PLC | 看跌 | 看跌 |
AIStockmoo 评分
1.8
| 分析师共识 | 4.0 |
| 内部交易活动 | NA |
| 价格波动 | 4.0 |
| 技术平均移动指标 | 1.5 |
| 技术振荡指标 | -2.5 |
| 平均 | 1.75 |
|
UK-based LivaNova was born of a combination between Cyberonics in the us and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management and heart valve businesses. It derives roughly half of its revenue from the us market, another 21% from Europe, and the remainder from the rest of the world. |
|
| 部门 | Healthcare |
| 行业 | Medical Devices |
| 投资方式 | Small Core |
| 内部持股比例 | 0.33% |
| 机构持股比例 | 104.39% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 64.00 (Needham, 58.53%) | 购买 |
| 中 | 60.00 (48.63%) | |
| 低 | 55.00 (Goldman Sachs, 36.24%) | 购买 |
| 平均值 | 59.00 (46.15%) | |
| 总计 | 4 购买, 1 保留 | |
| 平均价格@调整类型 | 41.04 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Needham | 17 Mar 2025 | 64.00 (58.53%) | 购买 | 41.41 |
| 26 Feb 2025 | 64.00 (58.53%) | 购买 | 41.45 | |
| Barclays | 07 Mar 2025 | 56.00 (38.72%) | 保留 | 39.17 |
| Goldman Sachs | 03 Mar 2025 | 55.00 (36.24%) | 购买 | 41.72 |
| Mizuho | 26 Feb 2025 | 60.00 (48.63%) | 购买 | 41.45 |
| Stifel | 26 Feb 2025 | 60.00 (48.63%) | 购买 | 41.45 |
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 26 Mar 2025 | 公告 | LivaNova to Announce First-Quarter 2025 Results |
| 25 Feb 2025 | 公告 | LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Guidance |
| 21 Feb 2025 | 公告 | LivaNova to Present at the Barclays Global Healthcare Conference |
| 21 Jan 2025 | 公告 | LivaNova to Announce Fourth-Quarter and Full-Year 2024 Results |
| 06 Jan 2025 | 公告 | LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合